Solid Tumors and Adjuvant Immunotherapy
Clinical research in solid tumors with resectable disease and an intermediate-high risk of recurrence, centered on immune checkpoint inhibitors and tumor mutational burden– or microsatellite instability-selected populations.
- Atezolizumab
- Tiragolumab
- Resectable malignancies
The focus includes adjuvant treatment strategies for biomarker-defined tumors in oncology.
HER2-Positive Early Breast Cancer
Research activity in HER2-positive early breast cancer addresses targeted therapy use in the early-stage setting, with attention to treatment delivery in routine oncology care.
- Pertuzumab
- Trastuzumab
- Early breast cancer
The therapeutic interest extends to HER2-directed therapy combinations used for patients with localized disease.
Subcutaneous Fixed-Dose Combination Therapy
Investigation of subcutaneous administration in HER2-directed treatment reflects interest in formulation-based approaches for breast cancer care.
- Fixed-dose combination
- Subcutaneous delivery
- Anti-HER2 therapy
These studies relate to treatment options designed for early breast cancer management in outpatient settings.
Oncology Care Delivery
Clinical research also examines the practical use of oncology treatments in terms of healthcare professional time and patient time associated with administration routes and regimen choices.
- Treatment administration
- Outpatient oncology
- Care pathway efficiency
This area is linked to treatment delivery considerations in breast cancer and targeted cancer therapy.
